Research Article


2017, 10(5): 1651–1661


A pH-switched mesoporous nanoreactor for synergetic therapy

Zhengqing Yan1,2, Andong Zhao1,2, Xinping Liu1,2, Jinsong Ren1, and Xiaogang Qu1 (*)

View Author's information

1 Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
2 University of Chinese Academy of Sciences, Beijing 100039, China

Keywords: Zinc oxide, mesoporous nanoreactor, non-specific degradation, controllable release, fluorescent imaging
Full article PDF
Cite this article(Endnote)
Share this article

views: 144

Citations: 0

  • Abstract
  • References
  • Electronic Supplementary Material
ABSTRACT Zinc oxide nanoparticles (ZnO NPs), as a new type of pH-sensitive drug carrier, have received much attention. ZnO NPs are stable at physiological pH, but can dissolve quickly in the acidic tumor environment (pH < 6) to generate cytotoxic zinc ions and reactive oxygen species (ROS). However, the protein corona usually causes the non-specific degradation of ZnO NPs, which has limited their application considerably. Herein, a new type of pH-sensitive nanoreactor (ZnO-DOX@F-mSiO2-FA), aimed at reducing the non-specific degradation of ZnO NPs, is presented. In the acidic tumor environment (pH < 6), it can release cytotoxic zinc ions, ROS, and anticancer drugs to kill cancer cells effectively. In addition, the fluorescence emitted from fluorescein isothiocyanate (FITC)-labeled mesoporous silica (F-mSiO2) and doxorubicin (DOX) can be used to monitor the release behavior of the anticancer drug. This report provides a new method to avoid the non-specific degradation of ZnO NPs, resulting in synergetic therapy by taking advantage of ZnO NPs-induced oxidative stress and targeted drug release.
Related Article
Cite this article

A pH-switched mesoporous nanoreactor for synergetic therapy. Nano Res. 2017, 10(5): 1651–1661

Download citation